Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS
Technology in Cancer Research & Treatment · 2026-07 · 25
DOI: 10.1177/15330338261473002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 24.07.2026. Verfasst von Xiangtian Xiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Myocarditis, Pharmacovigilance, Immune Checkpoint Inhibitors, Pericarditis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of Hospital Administration, NHC, China.
Abstract (Originalsprache)
Introduction
Immune-related adverse events (irAEs) pose considerable challenges to the clinical application of immune-checkpoint inhibitors (ICIs). Noninfectious myocarditis/pericarditis is a class of ICI-associated adverse events with a high fatality rate in real-world settings. This study aimed to comprehensively assess noninfectious myocarditis/pericarditis adverse events associated with ICIs.
Methods
Reports of ICI-related noninfectious myocarditis/pericarditis AEs were extracted from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis was performed using the reporting odds ratio (ROR). Serious and non-serious outcomes of noninfectious myocarditis/pericarditis cases were compared using the Mann-Whitney U test or chi-squared test, and clinical priority was assigned to signals by scoring five features on a 0- to 10-point scale. Factors associated with reporting were explored based on stratified analyses.
Results
Reports of noninfectious myocarditis/pericarditis AEs accounted for 1.67% of all ICI AE reports during the study period in the FAERS database. The median age of the patients was 70 years (interquartile range [IQR] 62–76), and 94.66% of reports had serious outcomes. Eight categories of noninfectious myocarditis/pericarditis AEs with positive RORs were identified. Noninfectious myocarditis/pericarditis AEs treated with ICIs were more frequently reported in male and older patients. Of note, 2, 3 and 3 AEs were identified as strong, moderate, and weak clinical priorities, respectively. The median time to onset (TTO) of strong, moderate and weak AEs for ICI treatments was 25 (IQR 14–61), 56 (IQR 24.50–116.25) and 124 (IQR 29–301) days, respectively. All disproportionality signals showed early-failure patterns, with the hazard of AE reporting decreasing over time.
Conclusions
This study suggests a significant disproportionality signal between ICIs and noninfectious myocarditis/pericarditis AEs, and the findings provide supporting evidence for clinicians in managing these AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Pharmacy, The People's Hospital of Lincang, Lincang, China.
- First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Wenting Zhang
Förderung
- National Institute of Hospital Administration, NHC, China
Zitieren
APA
Xiao, X., Su, H., Ma, C., Shu, Y., Ding, Y., Xu, P., & Zhang, W. (2026). Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261473002
Vancouver
Xiao X, Su H, Ma C, Shu Y, Ding Y, Xu P, et al. Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261473002
BibTeX
@article{Xiao2026,
author = {Xiao, Xiangtian and Su, Hongyan and Ma, Chengning and Shu, Yamin and Ding, Yiling and Xu, Pingping and Zhang, Wenting},
title = {Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261473002}
}
EUVIMED